August 2023 in “Expert Review of Clinical Pharmacology” This study found that while both topical cetirizine and minoxidil improved female pattern hair loss, minoxidil was significantly more effective in increasing hair density.
December 2022 in “Archives of Dermatological Research” This study found that topical cetirizine increased hair shaft thickness and improved clinical outcomes from the patients' perspective in female androgenetic alopecia compared to minoxidil alone, with similar side effect profiles.
1 citations
,
August 2022 in “Journal of Cosmetic Dermatology” This study found that combining 5% topical minoxidil and 5% topical spironolactone solutions may enhance treatment efficacy for androgenetic alopecia in both men and women, with significant reductions in vellus hair.
February 2022 in “Journal of Cosmetic Dermatology” In this study, a combination treatment of topical 2% flutamide and 5% minoxidil significantly improved hair density, hair thickness, and patient satisfaction more than 5% minoxidil alone in patients with androgenetic alopecia over six months.
11 citations
,
October 2021 in “Journal of The European Academy of Dermatology and Venereology” This study found that topical finasteride significantly increased hair count in men with androgenetic alopecia compared to placebo while maintaining similar efficacy to oral finasteride but with lower systemic exposure and a reduced impact on serum DHT levels, potentially minimizing sexual side effects.
7 citations
,
April 2021 in “Journal of Pharmacy and Pharmaceutical Sciences” This study found that while both cetirizine 1% and minoxidil 5% increased hair density in men with androgenetic alopecia, minoxidil showed a significantly higher improvement, and both treatments lost effectiveness after 8 weeks without use; cetirizine was well-tolerated with no significant adverse reactions.
10 citations
,
December 2020 in “Dermatologic Therapy” This study found that topical minoxidil 5% gel and spironolactone 1% gel were both effective treatments for androgenetic alopecia, with a combination of both providing the best clinical response and achieving 100% effectiveness among participants.
27 citations
,
October 2020 in “Drugs” This article reviews the development milestones of clascoterone up to its first approval for treating acne vulgaris, reporting no new clinical results for androgenetic alopecia.
59 citations
,
July 2020 in “Journal of The American Academy of Dermatology” This study concluded that oral minoxidil is an effective and well-tolerated alternative to topical minoxidil for healthy patients struggling with application-related compliance issues.
30 citations
,
January 2020 in “Fertility and Sterility” This review discusses the evidence for post-finasteride syndrome as a condition potentially induced by finasteride and dutasteride, associating them with sexual dysfunction, depression, anxiety, and suicidal ideation in a subset of men, and reports no new clinical results.
11 citations
,
December 2019 in “Dermatologic Therapy” This systematic review suggests that topical ketoconazole may improve hair regrowth and thickness in both animal and human studies for androgenetic alopecia, but further randomized controlled trials are needed.
53 citations
,
August 2019 in “Journal of The American Academy of Dermatology” This study observed that low-dose oral minoxidil and topical minoxidil 5% solution both improved hair density in women with female-pattern hair loss, but oral minoxidil may offer advantages in reducing hair shedding.
3 citations
,
August 2019 in “Journal of The American Academy of Dermatology” Clascoterone safely promotes hair growth similar to minoxidil.
10 citations
,
October 2018 in “Sexual medicine reviews” This review discusses sexual side effects in men with androgenic alopecia treated with 5-alpha reductase inhibitors and reports no new clinical findings.
36 citations
,
September 2018 in “American Journal of Clinical Dermatology” This study found that a topical combination of 0.25% finasteride and 3% minoxidil may increase hair diameter more effectively than 3% minoxidil alone in postmenopausal women with female pattern hair loss.
43 citations
,
July 2018 in “Journal of The European Academy of Dermatology and Venereology” This study found that a topical solution combining 0.25% finasteride with 3% minoxidil significantly improved hair growth, as measured by hair density, diameter, and global assessment, in men with androgenetic alopecia, compared to 3% minoxidil alone, over 24 weeks without systemic adverse effects reported.
16 citations
,
January 2018 in “International Journal of Trichology” In this study, minoxidil significantly downregulated interleukin-1 alpha expression in human keratinocyte cells, suggesting an anti-inflammatory effect that may be a mechanism of action in treating alopecia.
1 citations
,
April 2017 in “Journal of Investigative Dermatology” This study found that a novel 15% topical minoxidil solution achieved a clinically significant hair regrowth response in 60% of women with female pattern hair loss who did not respond to 5% minoxidil, without increasing adverse events.
57 citations
,
July 2016 in “The Journal of Sexual Medicine” This study concluded that 5α-reductase inhibitors were linked to increased sexual dysfunction in men with benign prostatic hyperplasia, but not in men with androgenetic alopecia.
8 citations
,
January 2016 in “European Journal of Plastic Surgery” This study found that plasma rich in growth factors was a safe and more effective treatment for androgenetic alopecia than topical minoxidil, showing greater improvements in hair growth phases.
42 citations
,
December 2015 in “International Journal of Clinical Pharmacology and Therapeutics” This study found that applying a novel 0.25% finasteride solution to the scalp can effectively reduce scalp DHT levels in men with androgenetic alopecia, potentially reducing systemic side-effects.
14 citations
,
January 2015 in “Current problems in dermatology” This review addresses treatment approaches for female pattern hair loss, highlighting that combining different therapies may be more effective than single treatments, but no new results are reported.
11 citations
,
September 2013 in “Journal of the Egyptian Women's Dermatologic Society (Print)” Various treatments exist for hair loss, but more research is needed for better options.
134 citations
,
August 2012 in “The Journal of Clinical Psychiatry” This study found that former finasteride users with persistent sexual side effects reported significantly higher rates of depressive symptoms and suicidal thoughts compared to controls.
81 citations
,
August 2011 in “Journal of The American Academy of Dermatology” In this study, latanoprost significantly increased hair density in young men with mild androgenetic alopecia after 24 weeks, suggesting it may stimulate hair follicle activity and treat hair loss.
This pilot study found that a novel regimen including NuH Hair led to significant hair growth in male patients with androgenic alopecia, regardless of atopy status, with quicker results when additional treatment components were used.
185 citations
,
March 2011 in “The Journal of Sexual Medicine” This study found that 94% of healthy men reported low libido and 92% reported erectile dysfunction as persistent sexual side effects after using finasteride for male pattern hair loss, with these effects lasting on average 40 months post-discontinuation.
10 citations
,
March 2004 in “Journal of the American Academy of Dermatology” The 5% minoxidil solution effectively treated hair loss with good tolerability.
43 citations
,
October 2002 in “International Journal of Cosmetic Science” This study found that 1% ketoconazole and 1% piroctone olamine shampoos increased hair shaft thickness and reduced hair shedding in men with telogen effluvium and androgenic alopecia associated with dandruff.
269 citations
,
August 2002 in “Journal of The American Academy of Dermatology” This study found that 5% topical minoxidil significantly increased hair regrowth and improved psychosocial perceptions of hair loss in men with androgenetic alopecia compared to 2% topical minoxidil and placebo over 48 weeks.
162 citations
,
August 2002 in “Survey of Ophthalmology” This study found that latanoprost induces significant growth and pigmentation of lashes and ancillary hairs, with effects mirroring both brief and chronic treatments observed in patients and animal models.
83 citations
,
December 2001 in “Journal of Investigative Dermatology” Minoxidil boosts hair growth by targeting adenosine and possibly sulfonylurea receptor 2B.
37 citations
,
January 2000 in “International Journal of Pharmaceutics” In a study using human scalp skin grafts on SCID mice, topical flutamide and finasteride significantly improved hair growth in male-pattern baldness compared to placebo, with flutamide showing superior results to finasteride.
145 citations
,
December 1999 in “Journal of Investigative Dermatology Symposium Proceedings” Finasteride 1mg helps reverse hair miniaturization in men and postmenopausal women.
63 citations
,
November 1999 in “British journal of dermatology/British journal of dermatology, Supplement” This study observes the expression of mRNA for androgen receptor, 5α‐reductase, and 17β‐hydroxysteroid dehydrogenase in human dermal papilla cells.
92 citations
,
January 1998 in “Dermatology” This study found that 2% ketoconazole shampoo improved hair density and anagen follicle proportion in androgenic alopecia similarly to minoxidil treatment, suggesting a potential role for Malassezia in inflammation.
216 citations
,
October 1997 in “American Journal of Ophthalmology” This study found that unilateral topical latanoprost use for glaucoma was associated with hypertrichosis and increased pigmentation of eyelashes in the treated eye compared to the untreated eye.
30 citations
,
January 1997 in “Journal of Dermatological Treatment” This study reported that a 0.005% finasteride solution may encourage hair regrowth and reduce balding areas in patients with androgenic alopecia, without significant absorption or adverse effects.
23 citations
,
March 1988 in “Biochemical Pharmacology” This study found that minoxidil inhibited prostacyclin production in various endothelial and smooth muscle cells in culture without affecting the synthesis of other cyclooxygenase products.
666 citations
,
September 1977 in “British Journal of Dermatology” This article presents a classification system for stages of female-pattern androgenetic alopecia to aid early diagnosis and mentions existing systems for rare male-pattern cases, but reports no new clinical results.
